Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells-Reference-Cited by-同舟云学术

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

Published:2014-04-26 Issue:7 Volume:89 Page:757-765
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Zent Clive S.¹,Taylor Ronald P.²,Lindorfer Margaret A.²,Beum Paul V.²,LaPlant Betsy³,Wu Wenting³,Call Timothy G.¹,Bowen Deborah A.¹,Conte Michael J.¹,Frederick Lori A.⁴,Link Brian K.⁵,Blackwell Sue E.⁵,Veeramani Suresh⁵,Baig Nisar A.¹,Viswanatha David S.⁴,Weiner George J.⁵,Witzig Thomas E.¹

Affiliation:

1. Division of Hematology; Mayo Clinic; Rochester Minnesota

2. Department of Biochemistry and Molecular Genetics; University of Virginia School of Medicine; Charlottesville Virginia

3. Department of Health Sciences Research; Mayo Clinic; Rochester Minnesota

4. Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester Minnesota

5. Holden Comprehensive Cancer Center and Department of Internal Medicine; University of Iowa; Iowa City Iowa

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23737/fullpdf

Reference58 articles.

1. Understanding and managing ultra high-risk chronic lymphocytic leukemia;Stilgenbauer;Hematol Am Soc Hematol Educ Program,2010

2. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine;Rai;J Clin Oncol,2002

3. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study;Keating;Blood,2002

4. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia;Osterborg;J Clin Oncol,1997

5. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions;Lozanski;Blood,2004

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls;Current Protocols;2023-10

2. Antibody‐mediated phagocytosis in cancer immunotherapy;Immunological Reviews;2023-08-21

3. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia;Blood Advances;2023-06-02

4. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial;Clinical Lymphoma Myeloma and Leukemia;2022-09

5. FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis;Antibodies;2022-07-05